Valuation: Genmab A/S

Market Cap 119B 18.45B 15.96B 14.9B 13.67B 25.71B 1,756B 26.12B 175B 68.63B 880B 69.28B 67.77B 2,910B P/E 2026 *
25.5x
P/E 2027 * 18x
Enterprise Value 139B 21.5B 18.59B 17.36B 15.93B 29.96B 2,046B 30.44B 204B 79.96B 1,025B 80.73B 78.96B 3,390B EV / Sales 2026 *
4.8x
EV / Sales 2027 * 3.89x
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day-1.76%
1 week+6.47%
Current month+5.76%
1 month+5.19%
3 months+18.47%
6 months+1.42%
Current year-3.03%
1 week 1,860.5
Extreme 1860.5
2,066
1 month 1,819.5
Extreme 1819.5
2,066
Current year 1,512
Extreme 1512
2,257
1 year 1,337
Extreme 1337
2,257
3 years 1,157
Extreme 1157
2,710
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-1.76%+6.47%+44.79%-23.64% 18.45B
+8.49%+20.55%+70.77%+103.07% 68.12B
-1.00%+4.57%+36.51%+65.25% 55.18B
-1.09%+32.96%+19.67%+509.20% 28.63B
+0.57%+18.87%+55.18%+5.18% 23.99B
+2.72%+3.41%-16.11%-12.04% 23.53B
-2.04%+10.84%+31.01%+628.97% 16.44B
-3.88%+16.98%+199.30%+350.94% 15.83B
+3.58%+1.96%+43.35%+162.22% 13.4B
+2.12%+3.54%+433.80%+202.14% 12.38B
Average +0.77%+10.87%+91.83%+199.13% 27.59B
Weighted average by Cap. +1.86%+12.67%+68.08%+163.71%

Financials

2026 *2027 *
Net sales 28.96B 4.48B 3.87B 3.62B 3.32B 6.24B 426B 6.34B 42.42B 16.65B 214B 16.81B 16.44B 706B 33.63B 5.2B 4.5B 4.2B 3.85B 7.25B 495B 7.36B 49.28B 19.34B 248B 19.53B 19.1B 820B
Net income 4.93B 763M 660M 616M 565M 1.06B 72.57B 1.08B 7.23B 2.84B 36.38B 2.86B 2.8B 120B 7.14B 1.1B 955M 892M 818M 1.54B 105B 1.56B 10.46B 4.11B 52.66B 4.15B 4.05B 174B
Net Debt 19.71B 3.05B 2.64B 2.46B 2.26B 4.25B 290B 4.32B 28.88B 11.34B 145B 11.44B 11.19B 481B 11.26B 1.74B 1.51B 1.41B 1.29B 2.43B 166B 2.46B 16.5B 6.48B 83.04B 6.54B 6.39B 275B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-08-10 DKK 1,966.00 -1.65% 31,130
26-08-07 DKK 1,999.00 +6.50% 316,139
26-08-06 DKK 1,877.00 -0.79% 90,714
26-08-05 DKK 1,892.00 +0.75% 94,097
26-08-04 DKK 1,878.00 +1.73% 86,208
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
1,999.00DKK
Average target price
2,403.92DKK
Spread / Average Target
+20.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock